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Abstract
Documented sensitivity of melanoma cells to PLX4720, a selective BRAFV600E inhibitor, is based on the presence of mutant
BRAF
V600E alone, while wt-BRAF or mutated KRAS result in cell proliferation. In colon cancer appearance of oncogenic
alterations is complex , since BRAF, like KRAS mutations, tend to co-exist with those in PIK3CA and mutated PI3K has been
shown to interfere with the successful application of MEK inhibitors. When PLX4720 was used to treat colon tumours, results
were not encouraging and herein we attempt to understand the cause of this recorded resistance and discover rational
therapeutic combinations to resensitize oncogene driven tumours to apoptosis. Treatment of two genetically different
BRAF
V600E mutant colon cancer cell lines with PLX4720 conferred complete resistance to cell death. Even though p-MAPK/
ERK kinase (MEK) suppression was achieved, TRAIL, an apoptosis inducing agent, was used synergistically in order to achieve
cell death by apoptosis in RKO
BRAFV600E/PIK3CAH1047 cells. In contrast, for the same level of apoptosis in HT29
BRAFV600E/PIK3CAP449T
cells, TRAIL was combined with 17-AAG, an Hsp90 inhibitor. For cells where PLX4720 was completely ineffective, 17-AAG
was alternatively used to target mutant BRAF
V600E. TRAIL dependence on the constitutive activation of BRAF
V600E is
emphasised through the overexpression of BRAF
V600E in the permissive genetic background of colon adenocarcinoma Caco-
2 cells. Pharmacological suppression of the PI3K pathway further enhances the synergistic effect between TRAIL and
PLX4720 in RKO cells, indicating the presence of PIK3CA
MT as the inhibitory factor. Another rational combination includes
17-AAG synergism with TRAIL in a BRAF
V600E mutant dependent manner to commit cells to apoptosis, through DR5 and the
amplification of the apoptotic pathway. We have successfully utilised combinations of two chemically unrelated BRAF
V600E
inhibitors in combination with TRAIL in a BRAF
V600E mutated background and provided insight for new anti-cancer
strategies where the activated PI3KCA mutation oncogene should be suppressed.
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Introduction
For a long time it has been appreciated that presence of KRAS
mutations highly correlates with colorectal cancer (CRC) progres-
sion and decreased patient survival. In addition, the more recently
identified BRAF mutations in CRC, do not co-exist with those in
KRAS and display a more potent transforming activity to be
associated with progression to metastasis [1,2]. Notable among the
apoptosis-inducing stresses are signalling imbalances resulting
from elevated levels of oncogene signalling, as mentioned earlier,
and DNA damage associated with hyper-proliferation. In contrast
to KRAS mutations, those in BRAF have the ability to cause
genomic rearrangements in colon cells that can potentially
sensitize them to apoptosis a major advantage in cancer
therapeutics, since deregulation of apoptosis can lead to growth
advantage in cancer cells. Yet other research has revealed how
apoptosis is attenuated in those tumours that succeed in
progressing to states of high-grade malignancy and resistance to
therapy [3,4]. The goal of most anti-tumour therapies, including
chemotherapy, radiation or newer targeted therapies is to
ultimately induce the death of tumour cells. Different chemother-
apies induce death of tumour cells by different mechanisms. These
include both apoptotic forms of cell death, as well as non-apoptotic
mechanisms such as autophagy, necrosis and mitotic catastrophe
[5]. However, the fraction of tumour cells that undergo non-
apoptotic death are significantly increased if apoptosis-related
mechanisms are inhibited [6]. Constitutive activation of MAPK
has been found in many different tumor cell lines and primary
tumors including colon cancer cells and tissues [7–9]. High
expression and constitutive activation of PI3K is also found in
gastric cancer and CRC [10]. Prominent among cell surface
molecules capable of initiating and tightly controlling apoptosis in
cancer cells is TRAIL, rendering it a promising anti-cancer agent
[11,12].
TRAIL induces apoptosis via interacting with its death
receptors (DRs), DR4 and DR5, which in turn results in death-
inducing signalling complex (DISC) formation and caspase-8
processing [13]. Caspase-8 activation can then result in caspase-3
activation through the mitochondrial-independent pathway, and/
or through the activation of Bid, a pro-apoptotic BH3-only Bcl-2
family member, which when cleaved induces the mitochondrial
release of apoptogenic factors such as Bax and Bak through the
mitochondrial-dependent pathway [14]. Despite the fact that
during colorectal carcinogenesis a marked increase in sensitivity to
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partially resistant to TRAIL-induced apoptosis [15].
The MAPKs that are activated by phosphorylation may also act
as important modulators of various apoptosis-inducing signals,
while the protective effect of extracellular signal-related kinase 1/2
(ERK1/2) on DR-induced apoptosis has been described [16,17].
Deregulation of this pathway by RAS and more recently BRAF
oncoproteins induce constitutive ERK1/2 activation, thereby
promoting cell growth and survival. Manipulation of the MAPK
signalling pathway could be a powerful means of treatment for
tumours with BRAF mutations especially those resistant to
TRAIL. Difluorophenyl-sulfonamine (PLX4720) targeting
BRAF
V600E cancer cell proliferation has recently been described
as potent and selective among the many tested clinically [18].
However application and dosage of this inhibitor should be
scrutinised since in can bind wild-type BRAF in KRAS mutant
cells and activate the MAPK pathway through CRAF The
mechanism of RAF regulation presents another strategy for its
inhibition [19–21].
The protein chaperone Hsp90 is required for the conforma-
tional maturation of several key signalling proteins, including
PI3K, p-Protein Kinase B (pAKT), NF-kB, CRAF and more
recently BRAF
V600E [22,23]. Inhibition of Hsp90 function with a
geldanamycin derivative, 17-allylamino-17-demethoxygeldanamy-
cin (17-AAG), has been shown to effectively inhibit Hsp90
function of malignant cells in vivo due to its great affinity for the
activated polymerized form of the molecular chaperone at
tolerable doses [24]. Although CRAF and ARAF are degraded
in cells that are exposed to 17-AAG, wild-type BRAF is not found
in an Hsp90 complex, while BRAF
V600E degradation leads to
MAPK inhibition, cell-cycle arrest, and apoptosis with concom-
itant antitumour activity in vivo [22].
Here we compare the selective BRAF
V600E inhibitor PLX4720
with the Hsp90 inhibitor 17-AAG, in colon cancer cells. Recorded
resistance to PLX4720 is attributed to the activating PIK3CA
mutations that coexist with BRAF
V600E. Treatment with 17-AAG
is more responsive, potentially due to the multiple oncogenic
proteins that are Hsp90 clients. Cell death by apoptosis at these
conditions is significantly facilitated when TRAIL is concomitantly
administered, as compared to the innate sensitivity to TRAIL in
colon cancer cells bearing a single BRAF
V600E mutation.
Materials and Methods
Growth Inhibition Studies and Cytoxicity Assays
The Caco-2, Colo205, HT29, RKO, DLD-1 and SW620
human colon adenoma-carcinoma cell lines were obtained from
ATCC. The Caco-BR clones constitutively expressing active
BRAF
V600E proteins and the Caco-NEO9-empty vector clones
have been previously described [1,25]. For growth inhibition and
cytoxicity studies we used the sulforhodamine B (SRB) assay.
Methodology is listed in supplementary materials and methods
(File S1). For assessment and quantification of TRAIL-induced
apoptosis, the ELISA cell death kit by Roche (Indianapolis, IN)
was alternatively used according to the manufacturer’s protocol
that is highly sensitive and detects apoptotic nucleosomes in cell
lysates.
For blocking experiments cells were pre-incubated for 15
minutes with 2 mg/ml of the respective blocking antibody against
DR4 and DR5 and then stimulated with TRAIL with and without
pretreatment with 17-AAG. Photographs were taken using a
Nikon Eclipse T-200 (Tokyo, Japan) inverted phase-contrast
microscope equipped with an Olympus digital camera (Olympus
SP-51OU2, Hamburg, Germany).
Three-Dimensional Culture
For three-dimensional culture experiments, cells were grown in
24-well plates on 20% Matrigel that was allowed to set for 15
minutes at 37uC in order to form a gel of 1 mm thickness. The
bottom later was then covered with 2610
4 cells mixed 1:1 with 4%
Matrigel in a total volume of 600 ml. Growth medium containing
2% matrigel was replaced every 2 days and the cells were left to
grow for 12–14 days to allow development of extensive tubule
network, after which treatment were applied for indicated
incubation times. Photographs of the three-dimensional cultures
were taken using a Nikon Eclipse T-200 inverted phase-contrast
microscope equipped with an Olympus digital camera. The nuclei
were stained with Hoechst No. 33342.
Immunoblotting and Immunoprecipitation
Whole cell lysates were prepared with Nonidet P-40 (NP-40)
buffer containing protease inhibitors and were subject to Western
blot analysis or immunoprecipitation studies. Methodology and
antibody information is listed in supplementary materials and
methods (File S1). For immunoprecipitation of the NP-40
insoluble fractions, pellets were resuspended in NP-40 lysis buffer
and sonicated three times for 10 sec at 4uC using an MSE
Soniprep150 to give the insoluble fraction.
Suppression of BRAF
V600E and PIK3CA
H1047 expression by
RNA interference
The small inhibitory duplex shRNA oligo was cloned into the
HindIII and BglII sites in pSUPER (Oligoengine, Seattle, WA).
The sense strand of the shRNA pSUPER BRAF
V600E insert was
BRAFmutshRNA: gatccccGCTACAGAGAAATCTCGATttcaa-
gagaATCGAG-ATTTCTCTGTAGCtttttggaaa (Hingorani et al.,
2003). BRAFmutshRNA or vector control (pSUPER) plasmids or
siRNA- PIK3CA
H1047 (Darmacon) were transiently expressed into
cells using lipofectamin (Sigma).
DISC Analysis
The ligand affinity precipitation was done using biotin-
conjugated TRAIL (Bio-TRAIL) in combination with streptavi-
din-agarose beads. Methodology and antibody information is
listed in supplementary materials and methods (File S1). Ligand
affinity precipitates were washed 5 times with lysis buffer and the
protein complexes were eluted from the beads by the addition of
30 ml SDS sample buffer and heating at 95uC for 15 minutes.
Proteins were separated in SDS-PAGE and immunoblotted.
Immunofluorescence Microscopy
Immunostaining methodology is listed in supplementary
materials and methods (File S1). Briefly, cells were incubated with
indicated primary antibodies for 2 hours at room temperature,
while the secondary antibody was applied to the cells for 1 hour
also at room temperature. The nuclei were stained with Hoechst
and visualized with a Leica TCS SPE confocal laser scanning
microscope (Leica Lasertechnik, Heidelberg, Germany).
Flow cytometry and apoptosis assays
For immunostaining, cells were incubated with 50 mg/ml anti-DR4
or anti-DR5 on ice for 30 minutes. Surface expression of the receptors
on living cells (Hoechst negative) was analyzed using a LSRII flow
cytometer (BD Biosciences). M30 Cytodeath assay of caspase-3-
cleaved cytokeratine 18 or Annexin V-FITC/ Hoechst staining were
used for the assessment and quantification of TRAIL-induced
apoptosis according to the manufacturer’s protocols. Methodology is
listed in supplementary materials and methods (File S1).
BRAF, PIK3CA Predict PLX4720/17-AAG/TRAIL Effects
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Total RNA was extracted using TRIzol reagent (Invitrogen,
Karlsruhe, Germany). The extracted total RNA (3 mg) was reverse
transcribed into cDNA using the SuperScriptt II Reverse
Transcriptase (Invitrogen) according to the manufacture. RT–
PCR amplification was performed as previously described and
intensity values were measured using Molecular Dynamics
ImageQuant Software. All PCR products were normalized to
GAPDH expression [26].
Results
A small therapeutic window for PLX4720 efficacy in BRAF
mutant cells
To identify molecular modifiers in currently resistant cells that
influence the sensitivity of BRAF mutant cells to TRAIL induced
apoptosis, we recorded a panel of colon cancer cell lines to
determine their response to the BRAF inhibitor PLX4720, which
targets the mutated V600E form of BRAF. Given the frequent co-
occurrence of KRAS/ BRAF and PI3K pathway lesions, two of
the selected cell lines harbored both BRAF and PI3K pathway
mutations. In response to PLX4720 no concentration dependence
was observed for any of the cell lines tested and only a small
inhibitory effect was achieved upon treatment with the highest
concentration in HT29 and RKO cells (Figure 1A). Treatment
with PLX4720 managed to inhibit the phosphorylation of BRAF
kinase to a degree as compared to the increased pCRAF levels
only in the BRAF
V600E mutant cell lines (Colo205, RKO and
HT29). Further downstream the MAPK pathway, the inhibitory
effect was more pronounced with a sustained inhibition mainly on
pMEK and pERK levels in cell lines harboring BRAF and PI3K
pathway mutations. Sustained inhibitory effect on the MAPK
pathway had an immediate effect on cyclin D1 target gene, all be it
in a much shorter (1–4 hours) incubation period (Figure 1B,
Figure S1). The inhibitory effect of PLX4720 on MEK pathway in
shorter rather than longer incubation periods indicates a
potentially small therapeutic window for treatment efficacy. As
expected, cell lines that are wild-type for BRAF (Caco-2) or KRAS
mutant (DLD-1) increased their proliferation rate by about 20% as
compared to control untreated cell following treatment with
PLX4720, independently of their doubling, that was also described
by the increase of pMEK and pERK levels in these cells
(Figure 1A–B).
Potent inhibition of cell growth in BRAF
MT and activated
BRAF
WT cells using 17-AAG
Attenuation of the MAPK pathway through mutant BRAF
inactivation by 17-AAG, which inhibits Hsp90 function, could
underline reversal of observed TRAIL resistance. The same panel
of colon cancer cell lines was monitored for their response to 17-
AAG inhibitor. Significant cytotoxicity was observed in one BRAF
mutant cell line (HT29), while considerable was the extent of cell
toxicity in Colo205, RKO and SW620, cell lines with distinct
genetic background. Nevertheless, sensitivity seemed to correlate
to pATK levels rather than the PI3K mutation itself (Figure 2A,
1B). Regardless the co-occurrence of BRAF and PI3K pathway
mutations in RKO and HT29 cells, basal pAKT levels were
significantly increased only in the RKO cells indicating a
diminished activating potential for the PIK3CA mutation
(P449T) present in HT29 cells. Notably, sensitivity to 17-AAG
was observed only in cell lines with moderate pAKT levels (HT29,
DLD-1, Colo205 and SW620) (Figure 2A, 1B). Degradation of
mutant BRAF in HT29 cells but also wild-type BRAF in DLD-1
cells, activated by co-expression with mutant KRAS, account for
the inhibitory effect observed in cell growth (Figure 2B). To
determine whether BRAF
V600E is an Hsp90 client protein, we
tested its sensitivity using as a control CRAF, a known Hsp90
client. CRAF expression was much more rapidly and efficiently
degraded. As expected, the reduction in CRAF was accompanied
by decreased ERK phosphorylation only in BRAF/ KARS
mutant cells (Figure 2B). By testing whether BRAF and Hsp90
associate with each other, we established that both mutant BRAF
and wild-type BRAF activated by the upstream mutant KRAS, are
Hsp90 client proteins in HT29 and DLD-1 cells respectively. The
kinase-specific Hsp90 co-chaperone p50cdc37 was also found to
co-precipitate with mutant BRAF (Figure 2C, Figure S2).
Surprisingly, as previously shown by Dias and colleagues, we also
did not observe any binding of CRAF to Hsp90 in any cell line
(data not shown) possibly for reasons previously discussed [27].
Taken together, either mutated or activated BRAF is more
dependent on Hsp90-chaperone for its folding, stability and
oncogenic activity than wild-type inactive protein.
PLX4720 cooperates with TRAIL to commit cells to
apoptosis
In an attempt to render resistant colon cancer cell more
sensitive to RAF inhibitor treatment with PLX4720, TRAIL was
used as a synergistic agent. Resistance to TRAIL treatment as a
single agent appeared to strongly correlate with the PI3K pathway
mutational status. TRAIL conferred limited cytotoxicity in BRAF
mutant cells harboring activating mutations in PIK3CA whereas,
extensive apoptosis was recorded in cells like Colo205 harboring a
single BRAF mutation, at very small doses (10 ng/ml), comparable
to the sensitive DLD-1 cells (Figure 3A). As expected, highly
metastatic SW620 colon carcinoma cells were completely resistant
to TRAIL as were also the intermediate adenocarcinoma Caco-2
cells. Treatment of cells with PLX4720 followed by co-concom-
itant administration with the lowest dose of TRAIL (10 ng/ml)
induced increased cell death only in cells (RKO) harboring a
BRAF mutation and high pAKT levels. The combination of
PLX4720 with TRAIL was not beneficial to already sensitive to
TRAIL cells, but was additive in cells harboring a BRAF mutation
only (Colo205) (Figure 3B). Notably previously sensitive to TRAIL
DLD-1 cells were rescued during the combined treatment of
TRAIL with PLX4720 suggesting that the presence of wild-type
BRAF may interfere with the apoptotic outcome. Conferred
resistance to the therapeutic combination by wild-type BRAF was
also confirmed in two independent and genetically similar colon
cancer cell lines, DLD-1 and HCT116 (Figure S3), indicating only
wild-type BRAF as the exclusionary factor for colon cancer
treatment with PLX4720.
The combination efficacy of BRAF inhibition and TRAIL
treatment was also applied to a three-dimensional (3D) cell culture
system as an in vitro tumor model where a significant apoptotic
effect was recorded. After two weeks of cell growth and tubule
formation within the spheroid structures, PLX4720/ TRAIL
induced caspase-3 activation and nuclear fragmentation was
evident (Figure 3C). This provides further evidence that this
combinatorial treatment can also be efficient in vivo.
Combined inhibition of BRAF and PIK3CA increases TRAIL
induced apoptosis in RKO cells
The antiproliferative effect in response to the combined
treatment involving the mutant BRAF inhibition and the
induction of the apoptotic TRAIL pathway could be related to
the PI3K mutational status. In order to answer this question, the
molecular mechanism underlying this effect, was analyzed.
BRAF, PIK3CA Predict PLX4720/17-AAG/TRAIL Effects
PLoS ONE | www.plosone.org 3 June 2011 | Volume 6 | Issue 6 | e21632Figure 1. Presence of BRAF mutations are not selective for efficient PLX4720 treatment in colon cancer cells. (A) Cell survival for a
panel of colon cancer cell lines treated with the selective for mutant BRAF pharmacologic inhibitor PLX4720. The values are the average of three
independent experiments andarepresented as fold changeof the absorbance of treated/ untreated cells, for each condition. Thenumberof viable cells
wasassayedbySRB24 hoursaftertreatment. Treatmentconditionsareprovidedalongthetoponeach column.*P,0.05,**P,0.01 vsCtr-untreated.(B)
Total cell lysates harvested from cells treated for 4 hours with 1 mM PLX4720 were immunoblotted for the indicated antibodies. Proteins are quantified
against a-tubulin and pERK levels against total ERK using the untreated condition of each cell line as a reference to the treated one.
doi:10.1371/journal.pone.0021632.g001
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PLoS ONE | www.plosone.org 4 June 2011 | Volume 6 | Issue 6 | e21632Figure 2. Presence of BRAF
V600E, an Hsp90 client protein, confers sensitivity to 17-AAG in colon cancer cells. (A) Cell survival for a
panel of colon cancer cell lines treated with the Hsp90 pharmacologic inhibitor 17-AAG. The values are the average of three independent
experiments and are presented as fold change of the absorbance of treated/ untreated cells, for each condition. The number of viable cells was
assayed by SRB 24 hours after treatment. Treatment conditions are provided along the top on each column. *P,0.05, **P,0.01, ***P,0.001 vs
Ctr-untreated. (B) Total cell lysates harvested from cells treated for indicated time points with 100 nM 17-AAG were immunoblotted for the indicated
antibodies. Proteins are quantified against a-tubulin. (C) Total cell lysates from indicated cell lines were immunoprecipitated with BRAF and the
complexes were immunoblotted with Hsp90, BRAF and Cdc37, which is right bellow the heavy chain (HC) of the antibody.
doi:10.1371/journal.pone.0021632.g002
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PLoS ONE | www.plosone.org 5 June 2011 | Volume 6 | Issue 6 | e21632Figure 3. PLX4720 sensitises RKO cells to TRAIL-induced apoptosis. (A) Cytotoxic effects of the apoptotic agent TRAIL in a panel of colon
cancer cell lines. The values are the average of three independent experiments and are presented as fold change of the absorbance of treated/
untreated cells, for each condition. The number of viable cells was assayed by SRB 16 hours after treatment. Treatment conditions are provided along
the top on each column. *P,0.05, **P,0.01, ***P,0.001.( B) Combined treatment with 1 mM PLX4720 for 8 hours and concomitant administration of
10 ng/ml TRAIL for 16 hours in a panel of colon cancer cell lines. Cell viability assayed by SRB 24 hours after treatment. (C) Caspase-3 activation
analysed by immunofluorescence 24 hours after induction with TRAIL/ PLX4720 alone or in combination, in a 3D culture of RKO cells. Representative
confocal immunofluorescence images, double labelled with Hoechst (blue) and active caspase-3 (green). Original magnification 63x.
doi:10.1371/journal.pone.0021632.g003
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PLoS ONE | www.plosone.org 6 June 2011 | Volume 6 | Issue 6 | e21632Depletion ofeither mutant BRAF or PIK3CA, using PLX4720 or the
PI-103 inhibitor, that block PI3K signaling downstream of p110a, did
not induce any apoptotic response (Figure 4A, lanes 2–3) nor did their
combination (Figure 4A, lane 5). When TRAIL was used alone,
partial apoptosis was recorded (Figure 4A, lane 4). However,
combining the inhibition of mutant BRAF with TRAIL treatment
induced several markers of apoptosis including cleavage of Poly ADP
(Adenosine Diphosphate)-Ribose Polymerase (PARP) and caspases-3
activation (Figure 4A, lane 6). Inhibition of PIK3CA and
concomitant TRAIL treatment did not induce a significant apoptotic
response (Figure 4A, lane 7). A more potent growth-inhibitory effect
was elicited by the combination of the PI3KCA inhibition and the
concomitant treatment with PLX4720 and TRAIL in RKO cells that
resulted in increased apoptotic cell death (Figure 4A, lane 8).
Replacement of the PIK3CA-p110a inhibitor (PI-103) with a siRNA
against the PIK3CA
H1047 mutant in RKO, did not manage to
increase apoptotic cell death any further as compared to PI-103
(Figure 4A, lanes 13–14). BRAF depletion using shRNA against
mutantBRAFinsteadofPLX4720likewiseprovedlessefficientinco-
treatment protocols involving TRAIL (Figure S4).
Figure 4. Inhibition of PIK3CA increases the combination efficacy of TRAIL with PLX4720 in RKO cells. (A) Cells left untreated or treated
with either 1 mM PLX4720 or a PIK3CA pharmacologic inhibitor PI-103 (0.5 mM) for 24 hours. Combined treatment of PLX4720 for 8 hours with
concomitant administration of 25 ng/ml TRAIL for 16 hours was performed along side with TRAIL treatment alone for 16 hours. Combined inhibition
of mutant PI3K and BRAF using 0.5 mM PI-103 and 1 mM PLX4720 for 8 hours following concomitant administration of 25 ng/ml TRAIL for 16 hours.
Alternative depletion of mutant PIK3CA by transient transfection of 1.6 pmol siRNA against the PIK3CAH1047 present in RKO cells in combination
with all indicated parameters. Total cell lysates harvested from the indicated treatments were analyzed for the phosphorylation of downstream
targets and induction of apoptotic markers. (B) Cells left untreated or treated with either 1 mM PLX4720 or 1 mM PI-103 for 24 hours. Combined
treatment with PLX4720 for 8 hours and concomitant administration of 100 ng/ml TRAIL for 16 hours was performed along side with TRAIL
treatment alone for 16 hours. Combined inhibition of mutant PI3K and BRAF using PI-103 and PLX4720 following concomitant administration of
TRAIL and alternative depletion of mutant BRAF by transient transfection of 7 mg shRNA against the BRAFV600E present in HT29 cells in combination
with all indicated parameters.
doi:10.1371/journal.pone.0021632.g004
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PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e21632Inhibition of PIK3CA increases TRAIL induced apoptosis
in HT29 cells
When the same experimental approach was applied to HT29
cells, the combination of BRAF inhibition using PLX4720 and
TRAIL treatment was not any more advantageous than TRAIL
alone (Figure 4B, lanes 4 and 6). Depletion of PIK3CA using PI-
103 and concomitant treatment with TRAIL, rendered cells
slightly more prone to apoptosis, evident by increased PARP
cleavage and the decrease in pro-caspase-8 protein expression
(Figure 4B, lane 7). Nevertheless, the combination of the PI3KCA
inhibitor and concomitant treatment with PLX4720 and TRAIL
did not increase apoptotic cell death in HT29 cells that are
genetically similar to the RKO cell line and sensitive to the
combination just described (Figure 4B, lane 7). Even though, the
shRNA against mutant BRAF in RKO cells was not very efficient,
possible because of highly activated BRAF, its application in
HT29 seems to be able to sequester pMEK about 2-fold
(Figure 4B, lane 11) without any obvious impact in amplifying
apoptosis for any of attempted combination treatments.
17-AAG overcomes TRAIL resistance in HT29 cells
through enhanced apoptosis
Pretreatment of colon cancer cells with 17-AAG following
treatment with TRAIL significantly sensitized HT29 to TRAIL
and had a more mild effect on DLD-1 cells. As previously, the
combination of 17-AAG with TRAIL was not beneficial to cells
already sensitive to TRAIL (Colo205), nor seemed to be related to
the mutational background of the cells (Figure 5A). The synergistic
effect of 17-AAG and TRAIL significantly increased cell death as
compared to each drug alone, while the sensitivity to 17-AAG did
not correlate with the combination’s cytotoxicity.
Sensitivity to pretreatment with 17-AAG appeared to be directly
related to BRAF
V600E protein degradation in HT29 cells
(Figure 5B-upper panel). TRAIL alone has a sub-toxic effect on
partially resistant HT29 cells, while their combinatorial treatment
resulted in procaspase-8 processing and Bid cleavage leading to
caspase-3 activation and PARP cleavage. This suggests amplifica-
tion of the mitochondrial pathway to mediate apoptosis (Figure 5B-
lower panel). Independent caspase-9 processing in the presence of
17-AAG alone, suggests a mechanism of activation dependent on
degradation of either BRAF
V600E or Hsp90 itself (Figure 5B). To
determine whether this gained sensitivity to apoptosis was
dependent on the mutant BRAF and not a non-specific effect of
17-AAG on other Hsp90 client proteins, attenuation of mutant
BRAF in HT29 cells by shRNA
V600E managed to decrease
apoptotic cell death by 17-AAG (Figure 5C). Evidence of
significantly impaired apoptosis was evaluated using the M30
CytoDEATH assay, which measures a cleaved fragment of
cytokeratin 18 and Annexin V that measures apoptotic fractions
(Figure 5C). Interaction between Hsp90 and mutant BRAF was
impeded resulting to low BRAF/ pBRAF levels which appeared to
interfere with the amplification of apoptotic cell death, previously
attained by the combination of TRAIL with 17-AAG (Figure S5).
BRAFV600E incites rapid DISC formation and
engagement of the apoptotic machinery in response to
TRAIL
To further unravel the role of mutant BRAF as a single
mutational event, previously established stable clones overexpress-
ing the mutant protein in a permissive genetic background of
Caco-2 cells were analyzed
1. Significant cell death by apoptosis at
the lowest dose of TRAIL was observed in Caco-2 clones
overexpressing the mutant BRAF
V600E (Caco-BR cells). The
extent of apoptosis was comparable to that observed in Colo205
also bearing a single BRAF mutation, but also to that in DLD-1
cells (Figure 6A, Supporting Figure 6).
Analysis of the DISC complex formation in response to TRAIL
within 30 minutes indicated that caspase-8 and FADD are
recruited to the DISC far more efficiently in the Caco-BR13
and DLD-1 cells than in HT29 cells. In HT29 two mutational
pathways are activated, the MAPK and the PI3K pathway, and
may be antagonizing each other at the expense of remitting
apoptosis (Figure 6B, Supporting Figure 7). Induction kinetics of
apoptosis in Caco-BR cells showed that apoptosis was achieved
within two hours with the lowest concentration of TRAIL, while
only half time treatment with the highest dose was required for
efficient induction of apoptosis, as indicated by several key
apoptotic markers like proaspase-8 and Bid processing leading to
PARP cleavage (Figure S8). Activation of Bax following expedi-
tious mitochondrial release of proapoptotic Cytochrome C,
activation of caspase-3 and chromatin condensation within 30
minutes of TRAIL induction was confirmed by immunostaining,
correlated to DISC complex formation (Figure 6C).
PLX4720 requires TRAIL assistance to induce apoptotic
cell death in BRAF
V600E colon cancer cells
As previously observed the presence of mutant BRAF in colon
cancer cells, does not predict cell sensitivity to PLX4720 nor did
BRAF
V600E overexpression in the mutational permissive back-
ground of Caco-2 cells (Figure 7A). Limited response to PLX4720
treatment is most likely due to the ambivalence overexpression and
phosphorylation of CRAF in response to the mutant BRAF stable
induction, but also due to the constitutive activation of MEK/
ERK phosphorylation (Figure S9). In order to facilitate cell death,
TRAIL was administered in combination with PLX4720.
Following exposure to low concentration of TRAIL, cells were
sensitized to the combination whereas at higher concentration the
advantage was lost due to the conferred sensitivity of BRAF
V600E
to TRAIL treated cells. Sensitivity of Caco-BR cells to TRAIL and
conferred sensitivity following treatment with PLX4720 was also
confirmed in 3D culture conditions. Caspase-3 activation and
nuclear fragmentation indicated engagement to apoptotic cell
death (Figure 7B).
17-AAG requires longer incubation periods to induce cell
death in the presence of dominant BRAF
V600E
The overexpression of mutant BRAF in colon adenocarcinoma
cells had quite the opposite effect of the anticipated increase in
sensitivity to the 17-AAG inhibitor. Significantly longer (4-day)
treatment periods with 17-AAG were required to achieve an
antiproliferative effect in Caco-BR cells (Figure 8A) comparable to
that achieved in HT29 cells in 24 hours (Figure 2A). Partial
degradation of mutant BRAF and insufficient MAPK pathway
inhibition in Caco-BR cells overexpressing mutant BRAF
V600E,
appear to preclude cell sensitivity to 17-AAG (Figure S10),
regardless of the interaction between mutant BRAF and Hsp90 in
the Caco-BR cells (Figure 8B).
Pathways for BRAF
V600E sensitization of colon cells to
TRAIL-induced apoptosis
Following mutant BRAF
V600E overexpression, the phosphory-
lation of both BRAF/ CRAF kinases was significantly increased,
which resulted in the downstream activation of MEK but not
ERK signalling (Figure 9-upper panel, lanes 3–4). Detailed
characterisation of this MAPK pathway activation and its cell
tumourorigenic effects have been described elsewhere [1].
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PLoS ONE | www.plosone.org 8 June 2011 | Volume 6 | Issue 6 | e21632Figure 5. 17-AAG sensitises HT29 cells to TRAIL-induced apoptosis. (A) Cytotoxic effects of the combined treatment using 17-AAG and
concomitant administration of TRAIL in a panel of colon cancer cell lines. The values are the average of three independent experiments and are
presented as fold change of the absorbance of treated/ untreated cells, for each condition. The number of viable cells was assayed by SRB 24 hours
after treatment. Treatment conditions are provided along the top on each column. *P,0.05, **P,0.01, ***P,0.001 vs Ctr-untreated. (B) Cells left
untreated or treated with 100nM 17AAG for 24 hours. Combined treatment of 17-AAG for 8 hours and concomitant administration of 100 ng/ml
TRAIL for 16 hours was performed along side with TRAIL treatment alone for 16 hours. Alternatively cells were pre-treated with 25 nM Z-VAD-FMK for
1 hour then 10 mM MG132 was added for another hour after which cell were treated with 100 nM 17-AAG for 22 hours. Finally cells were pre-treated
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the differential expression of some key apoptotic and anti-
apoptotic molecules, altered in such way that facilitates apoptosis.
Increased phosphorylation of the CRAF/ BRAF complex mainly
observed in the TRAIL sensitive cell lines Caco-BR and DLD-1
cells correlated with DR4 and DR5 overexpression observed on
the cell surface (Figure 9-lower panel, lanes 3-4 and 8; Figure S11).
Pro-apoptotic proteins including Bad, Bid and Bax were also
found overexpressed in Caco-BR and DLD-1 cells, while anti-
apoptotic molecules like Bcl-2 remained unchanged (Figure 9-
lower panel, lanes 3–4 and 8). Overexpressed Bad allows Bax to
escape Bcl-2 control and drive apoptosis while Bid accumulation
caused by BRAF
V600E overexpression comprises the initial step
towards the sensitization process. Moderate intrinsic pBRAF
activity was found in HT29 and RKO cells regardless the presence
of a BRAF mutation which was associated with potent activation
of the MAPK pathway (Figure 9-upper panel, lanes 6–7). This
observation raised the question whether sensitivity to TRAIL
induced apoptosis was associated with the constitutive BRAF
phosphorylation. Regardless activation of the CRAF/ BRAF
complex and TRAIL receptor overexpression in RKO cells
(Figure 9-upper panel, lane 7), resistance to TRAIL was recorded
(Figure 3A), potentially due to the concomitant activating PIK3CA
mutation. Towards this end, we hypothese that the sensitivity of
DLD-1 cells to TRAIL is not affected by the concomitant presence
of KRAS and PIK3CA mutations because of the constitutive
activation of pBRAF in these cells (Figure 9). In contrast, Colo205
cells that did not overexpress the CRAF/ BRAF complex
(Figure 9-upper panel, lane 5), but did express only marginally
the TRAIL receptors and anti-apoptotic BID (Figure 9-lower
panel, lane 5), were successfully committed to apoptosis possibly
because of the dominant BRAF
V600E presence (Figure 3A).
Ubiquitination of DR4 following treatment with 17-AAG
affects its transcriptional regulation
Significant downregulation of DR4 on the cell surface was
observed following treatment with 17-AAG alone or in combina-
tion with TRAIL in HT29 cells (Figure 5B-upper panel, lane 2;
Figure S12). Immediately a question was raised, regarding the
increased apoptosis attained under these conditions. Similar DR4
processing in the presence of 17-AAG was not observed in cells
sensitive to 17-AAG inhibitor like DLD-1 and Caco-BR13 cells
(Supporting Figures 13, 14). TRAIL alone did not cause any
visible proteolysis to either of DRs nor to BRAF/ CRAF
expression as compared to the significant degradation of RAF
isoforms accompanied by decreased pERK in the presence of 17-
AAG (Figure 5B-upper panel, lanes 2–3). The presence of the
proteasome inhibitor MG132 managed to suppress 17-AAG-
induced BRAF and DR4 degradation in HT29 cells, while CRAF
was irreversibly degraded (Figure 5B-upper panel, lane 7). To
determine whether DR4 downregulation resulted from decreased
pERK, which accompanies BRAF/ CRAF degradation, HT29
cells were treated with the MEK inhibitor UO126 (Figure 5B-
upper panel, lane 6) . Inhibition of MEK-ERK signaling resulted
in DR4 degradation confirming our model and previous findings,
regarding DR been regulated through a MEK-dependent pathway
due to increased pERK in the presence of TRAIL and KRAS
G12V
[17].
By adopting the double inhibition strategy it was shown that
BRAF
V600E serves as an Hsp90 client, since a marked increase in
RAF isoforms in the NP-40 insoluble fraction was observed
(Figure 10A, lane 7). To our surprise DR4 was also detected in the
same fraction suggesting that DR4 could also be an Hsp90 client
protein targeted for degradation (Figure 10B, lane 7). Even though
DR5 was not degraded during 17-AAG treatment, it was also
found accumulated in the NP-40 insoluble fraction at all
conditions (Figure 10B, lane 7). This is more likely to reflect
DRs attached on the cell membrane and dragged into the
insoluble. Immunoprecipitation of the insoluble fraction following
the double inhibition treatment showed ubiquitin accumulation
confirming our hypothesis that DR4 gets ubiquitinated upon
treatment with 17-AAG, whereas attempts to co-immunoprecip-
itate Hsp90 and DR4/5, were unsuccessful (Figure 10B, lane 5).
Furthermore, during the double inhibition treatment pERK
activity remained suppressed in the cytosolic extracts, while DR4
was rescued. This should not negate MEK-ERK dependent
regulation of DR4, since proteins found in an ubiquitinated state
should have their signaling ability impaired, which is depicted by
the selective mRNA downregulation of DR4 at these conditions
(Figure S15). Nevertheless, regardless complete absence of DR4 in
HT29 cells, apoptosis was amplified in the combined treatment via
the DR5.
17-AAG sensitizes HT29 cells to TRAIL-induced apoptosis
via DR5
To prove our hypothesis regarding DR5 being the mediator of
apoptosis following treatment with 17-AAG, HT29 cells were pre-
treated with a blocking antibody against DR4 or DR5 and then
subjected to TRAIL treatment. Inhibition of cell death was
achieved in the presence of the blocking Ab against DR5 but not
against DR4, regardless TRAIL been administered alone or in
combination with 17-AAG. In addition, inhibition of cell death
was also achieved when both blocking antibodies were combined
during pretreatment (Figure 11A-B). Data obtained so far suggest
that increased apoptosis in HT29 cells after combined treatment of
17-AAG with TRAIL is mediated via DR5.
Discussion
Constitutive activation of signaling via EGFR, MAPK and
PI3K pathways can promote uncontrolled cell growth, tumor cell
survival as well as resistance to cytotoxic agents [28,29].
Inhibiting the source of activation, when due to activating
mutations (KRAS, BRAF, PI3K), is a complex task. Inhibition of
mutant BRAF
V600E using the selective PLX4720 inhibitor,
induces apoptosis in melanoma cells [18]. In contrast, the clinical
activity seen with PLX4032 in metastatic CRC was more modest
suggesting the biology behind this type of cancer is more
heterogeneous [30]. Initiation and progression of CRC proceeds
through a series of genetic alterations involving oncogenes and
tumour suppressor genes, therefore prolonged and substantial
suppression can only be achieved in combination therapy. In the
present study we present the anti-proliferative effects of the
pharmacological application of PLX4720 as a single agent or in
combination with TRAIL, an inducer of apoptosis. Treatment
resistance recorded after exposure to PLX4720, had not been
anticipated considering studies reporting that BRAF mutant
pretreated with 60 mM UO126 for 8 hours after which TRAIL was added for another 16 hours. (C) Depletion of mutant BRAF by transient transfection
of 7 mg shRNA against the BRAF
V600E present in HT29 cells in combination with all indicated parameters described above. Apoptotic cell death after
24 hours was assayed using the Annexin V and M30 CytoDEATH assay.
doi:10.1371/journal.pone.0021632.g005
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PLoS ONE | www.plosone.org 10 June 2011 | Volume 6 | Issue 6 | e21632Figure 6. BRAF
V600E enhances DISC formation and apoptosis in response to TRAIL in colon cancer cells. (A) Cell survival for in Caco-BR
and Colo205 cells treated with TRAIL. The values are the average of three independent experiments and are presented as fold change of the
absorbance of treated/ untreated cells, for each condition. The cytotoxic effects of TRAIL were assayed by SRB. Treatment conditions are provided
along the top on each column. *P,0.05, **P,0.01, ***P,0.001 vs Ctr-untreated. (B) DISC complex analysis of functional proteins bound to Bio-TRAIL
at indicated time points. (C) Rapid induction of apoptosis within 30 minutes with respect to activation of apoptotic markers namely Tubulin, active
caspase-3, cytochrome C and Bax were analysed by immunofluorescence after addition of TRAIL. Representative confocal immunofluorescence
images, double labelled with Hoechst (blue), Mitotracker (Red) and indicated antibody (green). Original magnification 63x.
doi:10.1371/journal.pone.0021632.g006
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and did not correlate to the mutational background of the cells
[31]. In our study, even though inhibition of cell proliferation was
not accomplished by PLX4720, successful inhibition of down-
stream targets pMEK/ pERK with a profound effect on cyclin
D1 target gene was achieved in much shorter incubation periods
indicating a small therapeutic window. This observation illus-
trates the need for supportive combinatorial treatment. The
proliferative advantage previously described in cells bearing
KRAS mutant and wild-type BRAF following treatment with
PLX4720, was only observed for SW620 cells. In contrast, cell
numbers of DLD-1 cells remained unchanged suggesting a
possible implication of constitutive pBRAF in these cells.
Towards this end, when PLX4720 was co-administered with
TRAIL, in TRAIL sensitive DLD-1 cells, TRAIL induced
apoptosis was abrogated indicating wild-type BRAF and not
mutant KRAS, also present in DLD-1, as the exclusionary factor
for colon cancer treatment with PLX4720.
Pharmacological application of an indirect BRAF
V600E inhib-
itor, 17-AAG as a single agent was more efficient in colon cancer
cells. The antiproliferative effect was not selective to a specific
mutational background but to the levels of AKT phosphorylation.
Treatment with 17-AAG was least effective in RKO cell line,
where an increased phosphorylation of AKT is observed. Notably,
recent studies have shown that PIK3CA
MT and altered pAKT
activity can be critical markers for optimal tumour treatment
protocols [32,33]. Most encouraging was the selectively of 17-
AAG towards SW620, a metastatic colon cancer cell line, both Fas
and TRAIL-resistant [34]. Antiproliferative treatment with
PLX4720 could not be implemented within the small therapeutic
window predicted and the 17-AAG inhibitor could not eradicate
tumour cells under short time exposure at low concentration, their
combination with an apoptotic agent like TRAIL proved essential
and could intensify the results on cancer cell death. Thus, whether
the clinical goal is long-term exposure to low concentrations or
intermittent administration of relatively higher doses, the present
Figure 7. PLX4720 requires TRAIL synergy to induce an anti-proliferative effect. (A) Combined treatment with 1 mM PLX4720 for 8 hours
and concomitant administration of a low (10 ng/ml) or higher (50 ng/ml) concetration of TRAIL for 16 hours in Caco-BR cells. The values are the
average of three independent experiments and are presented as fold change of the absorbance of treated/ untreated cells, for each condition. The
cytotoxic effects of TRAIL were assayed by SRB 24 hours after treatment. *P,0.05, **P,0.01, ***P,0.001.( B) Caspase-3 activation analysed by
immunofluorescence 24 hours after induction with TRAIL/ PLX4720 alone or in combination, in a 3D culture of Caco-BR13 cells. Representative
confocal immunofluorescence images, double labelled with Hoechst (blue) and active caspase-3 (green). Original magnification 63x.
doi:10.1371/journal.pone.0021632.g007
BRAF, PIK3CA Predict PLX4720/17-AAG/TRAIL Effects
PLoS ONE | www.plosone.org 12 June 2011 | Volume 6 | Issue 6 | e21632study proposes rational drug combinations and their therapeutic
application that appears to offer superior opportunities provided
its tolerability in humans is acceptable, which will require phase I
clinical evaluation.
In order to achieve rapid induction of apoptosis, combination of
tested BRAF inhibitors with TRAIL in a concomitant approach
was applied in cell lines exhibiting some degree of sensitivity to
these inhibitors. When TRAIL was applied as a single agent
conferred limited cytotoxity in colon cells harboring activating
mutations in both the MAPK and PI3K pathways, whereas its
effect was significantly increased in cells with a single BRAF
mutation and accompanied by high pBRAF levels. If the presence
of dominant BRAF
V600E and high presentation of pBRAF serve as
a sensitizing factor to TRAIL induced apoptosis, then the
significantly activate wild-type BRAF in DLD-1 cell may also be
a TRAIL sensitizer. The combination of PLX4720 with
concomitant TRAIL induction managed to increase cell death
by apoptosis in RKO cells but not in HT29, even though
downstream targets like pMEK/ pERK levels were equally
inhibited. Interestingly, the presence of PIK3CA mutation and
the highly activated PI3K/Akt pathway in RKO cells does not
inhibit the synergism between PLX4720 and TRAIL, which can
be further exploited in the clinical application of these pharma-
cologic agents. The importance of this finding is further
emphasized by the fact that pharmacologic MEK pathway
inhibition of cell proliferation in BRAF mutant cancers may be
significantly decreased by the presence of activating PIK3CA
mutations [35].
In order to identify molecular modifiers that may influence cell
sensitivity to apoptosis even further, the proposed role of mutant
PIK3CA as an inhibitory factor was explored in our study [35].
Inhibitors of the PI3K/Akt signaling pathway gain considerable
attention in the treatment of CRC, especially since PI3K/Akt
pathway inhibition can modulate TRAIL induced apoptosis in
HT29 cells [34]. Down-regulation of PI3K by siRNA may also
sensitize colon cancer cells to TRAIL-induced apoptosis [36].
Herein, in order to improve cell response to BRAF inhibitor
treatment, attenuation of the PIK3CA
H1047 that co-exist with
BRAF
V600E in the relevant colon cancer cell lines was performed.
Deletion of PI3K using the PI-103 inhibitor alone or in
combination with either PLX4720 or TRAIL ranged from
inactive to moderate respectively and was only marginally
Figure 8. 17-AAG requires longer incubation periods to induce cell death. (A) Cell survival for Caco-BR and two colon cancer cell lines
treated with 17-AAG. The values are the average of three independent experiments and are presented as fold change of the absorbance of treated/
untreated cells, for each condition. The number of viable cells was assayed by SRB 4 days after treatment. Treatment conditions are provided along
the top on each column. *P,0.05, **P,0.01, ***P,0.001 vs Ctr-untreated. (B) Total cell lysates of Caco-BR13 and HT29 cells were immunoprecipitated
with BRAF and the complexes were immunoblotted with Hsp90, BRAF and Cdc37.
doi:10.1371/journal.pone.0021632.g008
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TRAIL combination in RKO cells. In conclusion, the presence of
PI3KCA mutation might not be interfering with the anti-
proliferative action of the PLX4720/ TRAIL combination, but
its suppression might offer an additional advantage towards
apoptotic cell death. Replacing PI-103 inhibitor with an siRNA
against PIK3CA
H1047 in RKO cells contributed equally to the
induction of apoptosis, illustrating once again the inhibitory role of
PIK3CA
H1047 as well as the benefits of using siRNA as a treatment
alternative. The combination efficacy of BRAF inhibition and
TRAIL treatment in the 2D cell culture system was also validated
in three-dimensional spheroid culture conditions, a pre-clinical
experimental model that may indicate the most promising
combinations to be later exploited in the clinic.
In a similar approach the PI-103 inhibitor was also used in
combination with TRAIL in HT29 cells. Increased sensitivity to
apoptosis was evident but there were no signs of further synergism
when incorporated into the PLX4720/ TRAIL combination. The
PI3K inhibitor PI-103 has been shown to efficiently cooperate
with TRAIL to synergistically induce apoptosis [37]. When
PLX4720 was replaced by shRNA against BRAF
V600E in HT29
cells, there was not additive effect on apoptotic cell death for any
of the treatment combinations, suggesting that the shRNA
approach in a heterozygous mutant background is not very
efficient. If our earlier hypothesis identifying activated-mutated
BRAF as a sensitizing factor is valid, the significantly low pBRAF
activity present in HT29 cells, as compared to RKO and DLD-1,
may explain the semi-resistant response not only to TRAIL but
also to the different combinations applied. In addition to the
moderate pBRAF activation, we also noted that the PIK3CA
P449T
activating mutation in HT29 is also of low activity which suggests
that none of the MAPK or the PI3K pathways is dominant. A
Figure 9. BRAF
V600E induces apoptosis related proteins in Caco-2 cells. (A) MAPK and apoptotic pathway protein expression analysis in
indicated cell lines.
doi:10.1371/journal.pone.0021632.g009
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PLoS ONE | www.plosone.org 14 June 2011 | Volume 6 | Issue 6 | e21632Figure 10. DR4 processing by 17-AAG in HT29 cells. (A) NP-40-insoluble fraction from HT29 cell treated as indicated were solubilized in 2% SDS
buffer and immunoblotted for the indicated antibodies. The proteasome inhibitor MG132, abrogated 17-AAG-induced loss of BRAF
V600E allowing the
protected but ubiquitinated BRAF, CRAF and DR4 protein to accumulate in the NP-40 insoluble fraction. (B) NP-40 soluble and insoluble fractions
were immunoprecipitated with DR4 and blotted with indicated antibodies.
doi:10.1371/journal.pone.0021632.g010
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shifting completely into the apoptotic pathway, achieving as a
result mild sensitization to apoptosis.
The synergistic effect between TRAIL and 17-AAG led to a
significantly apoptotic response in HT29 cells. Induction of
apoptosis was most likely achieved through amplification of the
mitochondrial pathway based on the extensive pro-caspase-9
processing in the combined treatment. It has been previously
demonstrated that combination of TRAIL with certain signaling
inhibitors results in enhancement of apoptosis through inhibition
of important pro-survival pathway components like AKT [38,39].
Activated AKT kinase is known to be an Hsp90 client and can be
targeted by 17-AAG [23]. Nevertheless, the anti-proliferative
effect of 17-AAG alone or in combination with TRAIL observed
Figure 11. 17-AAG sensitizes HT29 cells to TRAIL-induced apoptosis via the DR5. (A) Effects of anti-DR4/DR5 blocking antibodies on TRAIL/
17-AAG combination treatment in HT29 cells. Pre-treatment for 15 minutes with blocking antibody preceded all indicated treatments. Representative
images, original magnification 30x. (B) Cell viability of HT29 cells assays by SRB. Cell viability is presented as fold change of the absorbance of treated/
untreated cells, for each condition. *P,0.05, **P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0021632.g011
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between Hsp90 and BRAF either mutated or activated by
KRAS
G13D respectively, since depletion of mutant BRAF
V600E
in HT29 resulted to complete reversal of apoptotic cell death.
Interaction between Hsp90 and mutant BRAF is impaired
resulting to even lower pBRAF activity that interferes with the
amplification of apoptotic cell death.
To further unravel the role of mutant BRAF as a single
mutational event, a stable expression of BRAF
V600E was
performed in Caco-2 cells. Overexpression of the mutant protein
significantly sensitized Caco-2 cells to TRAIL induced apoptosis, a
response comparable to that of Colo205 cells also bearing a single
BRAF mutation. Functional analysis of DRs and apoptosis kinetics
revealed rapid DISC assembly and activation of the mitochondria-
dependent pathway after induction with TRAIL in BRAF
V600E
transformed and high pBRAF presenting DLD-1 cells. Neverthe-
less, overexpression of mutant BRAF does not confer any
sensitivity to the antiproliferative effect of PLX4720, unless a
small concentration of TRAIL is added to achieve an additive
effective response. Limited response to PLX4720 treatment is most
likely due to the ambivalence overexpression and phosphorylation
of CRAF in response to mutant BRAF stable induction. The
successful combination of PLX4720 with TRAIL in cells
overexpressing mutant BRAF was also confirmed in three-
dimensional culture conditions. Efficacy of TRAIL in Caco-BR
cells grown in spheroids holds great potential for future
application, especially when apoptosis is engaged in microsatellite
instable Caco-BR cells [1], potentially by circumventing their
impaired DNA repair mechanism in addition to deregulated
signaling pathways. The deregulate cell cycle Caco-BR cells are
under not only because of their deregulation of their mitotic check
point [1], but also because of the high levels of hyperpho-
sphorylated cyclinD1, might be accounted for the very late
response of the Caco-BR clones to 17-AAG treatment. The
unstable cell cycle renders Caco-BR cells able to escape 17-AAG
cell cycle targeted effects. On the other hand, HT29 cells have a
more stable cell cycle that can be more efficiently targeted by 17-
AAG, whereas DLD-1 cells harboring a KRAS mutation were also
found partially sensitive to 17-AAG, possibly because of their high
intrinsic pBRAF levels. Sensitivity of cancer cells to specific drugs
can be regulated through the expression patterns of the BH3-only
family members.
Overexpression of pro-apoptotic as compared to anti-apoptotic
factors was recorded following BRAF
V600E transformation and
was comparable to high pBRAF presenting DLD-1 and Colo205
cells. Recorded upregulation in DR4/ 5 serve as the initial step
towards the efficient DISC formation whereas Bid accumulation
provides the link between terminal effector processes and signaling
related alterations such as DNA integrity, cell attachment and
microtubule function. Simultaneous downregulation of Bcl-2
ensures Bax translocation to the mitochondrial membrane and
Cytochrome C release. Upregulation of pro-apoptotic proteins
may explain how increased sensitivity of Caco-BR cells to TRAIL-
induced apoptosis is achieved.
Previous studies describe the synergistic effect between TRAIL
and 17-AAG and the inhibitory effect of 17-AAG on DR4.
Although it has been well described how the ubiquitin system
regulates the proximal steps of the DISC assembly and its
components, ubiquitination of DR4 has not been observed before
[40]. Despite ubiquitin dependent proteolysis of DR4 accompa-
nied by an mRNA depended downregulation, lack of interaction
between Hsp90 and DR4 suggests that DR4 is targeted by the
ubiquitin aimed for HSp90. In this case internalization of DR4
must be more frequent as compared to DR5 or the protein
turnover is increased. Moreover, significant suppression of pERK
following BRAF degradation by 17-AAG has also contributed to a
MEK dependent DR4 downregulation in the presence of
attenuated BRAF
V600E activity. Nevertheless, apoptosis was
efficiently mediated through DR5 as determined by functional
analysis using specific DR5 blocking antibodies. Considering
occasions where inactivation of KILLER/ DR5 due to mutations
[41], or absence of its cell surface expression because of improper
transport to the cell surface [42], cells being treated with the
proposed combination of TRAIL/ 17-AAG will manage to escape
DR5 mediated apoptosis.
This study has analyzed in detail the role of BRAF/ KRAS/
PIK3CA mutation status of particular colorectal tumours on
predicting efficient therapeutic treatments with the BRAF and the
PI3K inhibitors as well as their rational combination with TRAIL.
Cell death by apoptosis when TRAIL was concomitantly
administered with PLX4720 or 17-AAG was significantly
increased suggesting that when BRAF
V600E or PIK3CA
H1047 exist
as dominant mutational events may confer sensitivity to TRAIL.
Supporting Information
Figure S1 Suppression of BRAF phosphorylation within
16 hours and rapid inhibition of pERK within an hour of
treatment with 1 and 10 mM of PLX4720 in RKO cells.
(TIF)
Figure S2 Complete experiment of immunoprecipita-
tion of indicated cell lines with BRAF and the complexes
subsequently immunoblotted first with Hsp90 and then
with BRAF and Cdc37, which is right bellow the heavy
chain (HC) of the antibody.
(TIF)
Figure S3 Combined treatment with 1 mM PLX4720 for
8 hours and concomitant administration of 10 ng/ml
TRAIL for 16 hours in DLD-1 and HCT116 colon cancer
cells. Cell viability assayed by SRB 24 hours after treatment.
**P,0.01, ***P,0.001.
(TIF)
Figure S4 Depletion of mutant BRAF by transient
transfection using indicated shRNA against the
BRAF
V600E present in HT29 cells and subsequent
treatment of cells with 100 ng/ml TRAIL. Total cell lysates
harvested for the described treatments were immunoblotted with
the indicate antibodies.
(TIF)
Figure S5 (B) Western blotting of HT29, HT-PS (empty
vector), HTShBR-1, -3 and -5 stable clones. Expression
levels of total and phosphorylated BRAF is shown accompanied by
phosphorylation status of ERK1/2.
(TIF)
Figure S6 A dose response with TRAIL was performed
for 16 hours in Caco-BR transformed cells and
BRAF
V600E mutant HT29 cells. The cytotoxic effects of
TRAIL were measured using the apoptosis ELISA kit by Roche.
Log percentage cell viability and fold change of the absorbance of
treated/ untreated cells, for each condition are presented.
(TIF)
Figure S7 Cell lysates and flow through controls of the
western blot analysis for the DISC immunoprecipita-
tion.
(TIF)
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PLoS ONE | www.plosone.org 17 June 2011 | Volume 6 | Issue 6 | e21632Figure S8 Induction kinetics of apoptosis at indicated
TRAIL concentrations and specific time points. Total cell
lysates harvested from cells treated for indicated time points following
treatment with 10 and 100 ng/ml TRAIL were immunoblotted for
the indicated antibodies. Proteins are quantified against a-tubulin.
(TIF)
Figure S9 Total cell lysates harvested from in Caco-BR
cells treated for 4 hours with indicated concentrations of
PLX4720 were immunoblotted for the indicated target
proteins. Proteins are quantified against a-tubulin.
(TIF)
Figure S10 Total cell lysates harvested from Caco-BR13
cells treated for indicated time points with 100 nM 17-
AAG were immunoblotted for the indicated antibodies.
Proteins are quantified against a-tubulin.
(TIF)
Figure S11 Cell surface expression of DR4 and DR5
analysed by means of flow cytometry following staining
with antibodies against DR4, DR5 and the secondary
GAM-PE antibody only (IgG-PE) that was used against
DR4 and DR5 in living cells (Hoechst negative). Blue line
indicates expression levels of DRs in parental Caco-2 cells.
Representative histograms from at least three independent
experiments are shown. Blue line indicates expression levels of
DRs in parental Caco-2 cells.
(TIF)
Figure S12 DR expression on the cell surface of HT29
cells. Downregulation of the DR4 was assayed by means of flow
cytometry following treatment with 100 nM 17-AAG alone or in
combination with 10 ng/ml TRAIL for 24 hours. Nearly 40% of the
DR4 was rescued in the presence of 10 mM MG132. Representative
histograms from at least four independent experiments are shown.
Blue line indicates expression levels of DRs in parental Caco-2 cells.
(TIF)
Figure S13 DR4 escapes 17-AAG dependent degradation
in DLD-1 cells. Cells were left untreated or treated with 150 nM
or 1 mM 17-AAG for 30 hours, or pre-treated with the 150 nM
17-AAG for 24 hours after which 10 ng/ml TRAIL was added for
another 16 hours or 10 ng/ml TRAIL alone was added for
16 hours. Alternatively cells were pre-treated with 25 nM Z-VAD-
FMK for 1 hour then 10 mM MG132 was added for another hour
after which cell were treated with 150 nM 17-AAG for 24 hours.
Protein extracts were separated into NP-40 soluble and NP-40
insoluble fractions and subjected to Western blot analysis.
(TIF)
Figure S14 Caco-BR13 cells were left untreated or
treated with a low 150 nM and a high 1 mM concentra-
tion of 17-AAG for 30 hours, or pre-treated with the 1 mM
17-AAG for 24 hours. Alternatively cells were pre-treated with
25 nM Z-VAD-FMK for 1 hour then 10 mM MG132 was added
for another hour after which cell were treated with 1 mM 17-AAG
for 24 hours. Protein extracts were subjected to Western blot
analysis. Picture shown is representative of three independent
experiments.
(TIF)
Figure S15 mRNA extracts from HT29 cells treated as
indicated were analysis by RT-PCR with regard to
TRAIL receptor, DR4 and DR5, transcriptional activity.
(TIF)
File S1 Supplementary Materials and Methods.
(DOC)
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